708 related articles for article (PubMed ID: 26091295)
41. Incidence and factors associated with active tuberculosis among people living with HIV after long-term antiretroviral therapy in Thailand: a competing risk model.
Gatechompol S; Sophonphan J; Ubolyam S; Avihingsanon A; van Leth F; Cobelens F; Kerr SJ
BMC Infect Dis; 2022 Apr; 22(1):346. PubMed ID: 35387594
[TBL] [Abstract][Full Text] [Related]
42. Vitamin A and D Deficiencies Associated With Incident Tuberculosis in HIV-Infected Patients Initiating Antiretroviral Therapy in Multinational Case-Cohort Study.
Tenforde MW; Yadav A; Dowdy DW; Gupte N; Shivakoti R; Yang WT; Mwelase N; Kanyama C; Pillay S; Samaneka W; Santos B; Poongulali S; Tripathy S; Riviere C; Berendes S; Lama JR; Cardoso SW; Sugandhavesa P; Christian P; Semba RD; Campbell TB; Gupta A;
J Acquir Immune Defic Syndr; 2017 Jul; 75(3):e71-e79. PubMed ID: 28169875
[TBL] [Abstract][Full Text] [Related]
43. Incidence and risk factors for tuberculosis in HIV-infected patients while on antiretroviral treatment in Cambodia.
Choun K; Thai S; Pe R; Lorent N; Lynen L; van Griensven J
Trans R Soc Trop Med Hyg; 2013 Apr; 107(4):235-42. PubMed ID: 23324313
[TBL] [Abstract][Full Text] [Related]
44. Effect of antiretroviral treatment on the risk of tuberculosis during South Africa's programme expansion.
Bachmann MO; Timmerman V; Fairall LR
AIDS; 2015 Nov; 29(17):2261-8. PubMed ID: 26544699
[TBL] [Abstract][Full Text] [Related]
45. Tuberculosis incidence after 36 months' isoniazid prophylaxis in HIV-infected adults in Botswana: a posttrial observational analysis.
Samandari T; Agizew TB; Nyirenda S; Tedla Z; Sibanda T; Mosimaneotsile B; Motsamai OI; Shang N; Rose CE; Shepherd J
AIDS; 2015 Jan; 29(3):351-9. PubMed ID: 25686683
[TBL] [Abstract][Full Text] [Related]
46. Effectiveness of a multivitamin supplementation program among HIV-infected adults in Tanzania.
Sudfeld CR; Buchanan A; Ulenga N; Spiegelman D; Mtisi E; Hertzmark E; Muya AN; Sando D; Mungure E; Mizinduko M; Fawzi WW
AIDS; 2019 Jan; 33(1):93-100. PubMed ID: 30289815
[TBL] [Abstract][Full Text] [Related]
47. Antiretroviral treatment-associated tuberculosis in a prospective cohort of HIV-infected patients starting ART.
Worodria W; Massinga-Loembe M; Mayanja-Kizza H; Namaganda J; Kambugu A; Manabe YC; Kestens L; Colebunders R
Clin Dev Immunol; 2011; 2011():758350. PubMed ID: 21197091
[TBL] [Abstract][Full Text] [Related]
48. High rates of loss to follow-up during the first year of pre-antiretroviral therapy for HIV patients at sites providing pre-ART care in Nigeria, 2004-2012.
Agolory SG; Auld AF; Odafe S; Shiraishi RW; Dokubo EK; Swaminathan M; Dalhatu I; Onotu D; Abiri O; Debem H; Bashorun A; Ellerbrock TV
PLoS One; 2017; 12(9):e0183823. PubMed ID: 28863160
[TBL] [Abstract][Full Text] [Related]
49. Prevalence of hepatitis B co-infection and response to antiretroviral therapy among HIV-infected patients in Tanzania.
Hawkins C; Christian B; Ye J; Nagu T; Aris E; Chalamilla G; Spiegelman D; Mugusi F; Mehta S; Fawzi W
AIDS; 2013 Mar; 27(6):919-927. PubMed ID: 23196935
[TBL] [Abstract][Full Text] [Related]
50. Predictors of weight loss after HAART initiation among HIV-infected adults in Tanzania.
Li N; Spiegelman D; Drain P; Mwiru RS; Mugusi F; Chalamilla G; Fawzi WW
AIDS; 2012 Mar; 26(5):577-85. PubMed ID: 22156968
[TBL] [Abstract][Full Text] [Related]
51. Incidence of active tuberculosis among people living with HIV receiving long-term antiretroviral therapy in high TB/HIV burden settings in Thailand: implication for tuberculosis preventive therapy.
Suwanpimolkul G; Gatechompol S; Kawkitinarong K; Ueaphongsukkit T; Sophonphan J; Siriyakorn N; Jirajariyavej S; Khusuwan S; Panarat P; Wannalerdsakun S; Saetiew N; Chayangsu S; Wiwatrojanagul S; Noopetch P; Danpornprasert P; Mekviwattanawong S; Fujitnirun C; Lertpiriyasuwat C; Han WM; Kerr SJ; Ruxrungtham K; Avihingsanon A;
J Int AIDS Soc; 2022 Apr; 25(4):e25900. PubMed ID: 35384317
[TBL] [Abstract][Full Text] [Related]
52. Paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome after early initiation of antiretroviral therapy in a randomized clinical trial.
Laureillard D; Marcy O; Madec Y; Chea S; Chan S; Borand L; Fernandez M; Prak N; Kim C; Dim B; Nerrienet E; Sok T; Delfraissy JF; Goldfeld AE; Blanc FX;
AIDS; 2013 Oct; 27(16):2577-86. PubMed ID: 24096631
[TBL] [Abstract][Full Text] [Related]
53. Tuberculosis after one year of combination antiretroviral therapy in Nigeria: a retrospective cohort study.
Akanbi MO; Achenbach CJ; Feinglass J; Taiwo B; Onu A; Pho MT; Agbaji O; Kanki P; Murphy RL
AIDS Res Hum Retroviruses; 2013 Jun; 29(6):931-7. PubMed ID: 23316724
[TBL] [Abstract][Full Text] [Related]
54. Risk of tuberculosis after antiretroviral treatment initiation: a comparison between efavirenz and nevirapine using inverse probability weighting.
Hermans SM; Manabe YC; Kiragga AN; Hoepelman AI; Lange JM; van Leth F
Antivir Ther; 2013; 18(4):615-22. PubMed ID: 23423604
[TBL] [Abstract][Full Text] [Related]
55. Earlier initiation of antiretroviral therapy, increased tuberculosis case finding and reduced mortality in a setting of improved HIV care: a retrospective cohort study.
Hermans SM; van Leth F; Manabe YC; Hoepelman AI; Lange JM; Kambugu A
HIV Med; 2012 Jul; 13(6):337-44. PubMed ID: 22296211
[TBL] [Abstract][Full Text] [Related]
56. Prognostic significance of the interval between the initiation of antiretroviral therapy and the initiation of anti-tuberculosis treatment in HIV/tuberculosis-coinfected patients: results from the TREAT Asia HIV Observational Database.
Han SH; Zhou J; Lee MP; Zhao H; Chen YM; Kumarasamy N; Pujari S; Lee C; Omar SF; Ditangco R; Phanuphak N; Kiertiburanakul S; Chaiwarith R; Merati TP; Yunihastuti E; Tanuma J; Saphonn V; Sohn AH; Choi JY;
HIV Med; 2014 Feb; 15(2):77-85. PubMed ID: 23980589
[TBL] [Abstract][Full Text] [Related]
57. Tuberculosis risk before and after highly active antiretroviral therapy initiation: does HAART increase the short-term TB risk in a low incidence TB setting?
Pettit AC; Jenkins CA; Stinnette SE; Rebeiro PF; Blackwell RB; Raffanti SP; Shepherd BE; Sterling TR
J Acquir Immune Defic Syndr; 2011 Aug; 57(4):305-10. PubMed ID: 21423024
[TBL] [Abstract][Full Text] [Related]
58. Incidence and predictors of mortality and the effect of tuberculosis immune reconstitution inflammatory syndrome in a cohort of TB/HIV patients commencing antiretroviral therapy.
Worodria W; Massinga-Loembe M; Mazakpwe D; Luzinda K; Menten J; Van Leth F; Mayanja-Kizza H; Kestens L; Mugerwa RD; Reiss P; Colebunders R;
J Acquir Immune Defic Syndr; 2011 Sep; 58(1):32-7. PubMed ID: 21654499
[TBL] [Abstract][Full Text] [Related]
59. Incidence and determinants of tuberculosis infection among adult patients with HIV attending HIV care in north-east Ethiopia: a retrospective cohort study.
Ahmed A; Mekonnen D; Shiferaw AM; Belayneh F; Yenit MK
BMJ Open; 2018 Feb; 8(2):e016961. PubMed ID: 29437750
[TBL] [Abstract][Full Text] [Related]
60. Tuberculosis, before and after Antiretroviral Therapy among HIV-Infected Children in Nigeria: What Are the Risk Factors?
Anígilájé EA; Aderibigbe SA; Adeoti AO; Nweke NO
PLoS One; 2016; 11(5):e0156177. PubMed ID: 27232185
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
